#GEX I’ve been buying back into this. Managed to double my money on the last trade but sold too early. Just missed out on the last big move as well.
I’m expecting a continuous rise into spud and drilling during Q3.
@Parsortix (#CLBX) shares were up nearly 100% this week, and quite deservedly so, given the recent newsflow. The company really is rubbing shoulders with giants, in this case a a Master Services Agreement with @AstraZeneca (#AZN). Indeed, whatever the agreement, the big win here is actually getting AZN to be named. Normally, international blue chip names do not reveal themselves, especially when small cap companies are involved.
Echoing what I wrote above, there was a one week sideways shuffle for CLBX above a rising 50 day moving average a couple of weeks ago, indicating a major move to the upside was on its way, and CLBX was mentioned as a turnaround ahead of this. They have since doubled. Fundamental investors, unless very well informed, would have had trouble matching this. https://t.co/KbbUkJnevM @ZaksTradersCafe
#CLBX Nice research collaboration with The Royal Marsden NHS Foundation Trust.
Prove that CTC-DNA profiling is useful in cancer clinical trials and Big Pharma will approach.